Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited ( the " Stock Exchange " ) take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Genscript Biotech Corporation 金斯瑞 生物 科技 股份有限公司 * ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 1548 ) ANNOUNCEMENT OF UNAUDITED CONSOLIDATED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30 , 2021 INTERIM RESULTS HIGHLIGHTS Revenue of the Group for the six months ended June 30 , 2021 was approximately US $ 229.6 million , representing an increase of 38.0 % as compared with approximately US $ 166.4 million recorded for the same period of 2020 , among which , the external revenue for non - cell therapy business was approximately US $ 195.7 million , representing an increase of 36.6 % as compared with approximately US $ 143.3 million for the same period of 2020 , and the revenue for cell therapy business was approximately US $ 33.9 million , representing an increase of 46.8 % as compared with approximately US $ 23.1 million for the same period of 2020 . Gross profit of the Group for the six months ended June 30 , 2021 was approximately US $ 138.6 million , representing an increase of 28.1 % as compared with approximately US $ 108.2 million recorded for the same period of 2020 , among which , the gross profit of non - cell therapy business was approximately US $ 104.7 million , representing an increase of 23.0 % as compared with approximately US $ 85.1 million for the same period of 2020 , and the gross profit of cell therapy business was approximately US $ 33.9 million , representing an increase of 46.8 % as compared with approximately US $ 23.1 million for the same period of 2020 . Loss of the Group for the six months ended June 30 , 2021 was approximately US $ 156.1 million , whilst loss of approximately US $ 160.5 million was recorded for the same period of 2020 .